IntelGenx Technologies Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating drug delivery systems. The company uses its unique multiple-layer delivery system to provide release of drugs in the gastrointestinal tract. It has also developed delivery technologies for the rapid delivery of drugs in the oral cavity based on quickly disintegrating films.
The company announced today that Dr. Rajiv Khosla has agreed to join IntelGenx’ board of directors. Dr. Khosla will bring a wealth of experience and expertise in oral drug delivery technology, pharmaceuticals and business development to the board of directors.
Dr. Khosla was recently named president, chief executive officer and a member of the board of directors of Orasi Medical. This company is a leading provider of clinical neurophysiology biomarkers, which is focused on the commercialization of magnetoencephaography in central nervous system drug and therapeutic device development. In January of this year, Dr. Khosla founded CEUTEC LLC, a private company that offers a full suite of business development activities to biotechnology, specialty pharmaceutical and venture capital firms.
From September 2005 to December 2010, Dr. Khosla was vice-president of business development at Biovail, a Canadian pharmaceutical company. During his stint at Biovail, Dr. Khosla successfully led the transaction process for over 75 deal opportunities in a variety of therapeutic areas. From 2003 to 2005, he was vice-president and general manager, pharmaceutical, of Sensient Technologies. Finally, from 1998 to 2003, Dr. Khosla served as senior business director of healthcare at ICI Group, where he managed a new worldwide healthcare business.
For more information on IntelGenx, please visit the company’s website at www.intelgenx.com